

Amendments to the Claims:

1-31. (Canceled)

32. (Currently Amended) A ~~pharmaceutical preparation for tolerization,~~ composition comprising
 (i) a pharmaceutically acceptable carrier and
 (ii) ~~an amount of an isolated human polypeptide effective for tolerizing an individual to an autoantigen, wherein: said human polypeptide consists~~ consisting of an amino acid sequence, wherein said amino acid sequence
 (a) defines a sequence motif containing core MHC binding residues comprising PV motif #1 (SEQ ID NO: 21), and
 (b) is based upon the structure of the binding pocket of ~~a an HLA-DR DRB1*0402 protein that, which HLA-DR protein is selected from the group consisting of HLA-DR2 and HLA-DR4, and is associated with a human autoimmune disease selected from Pemphigus Vulgaris (PV) or Multiple Sclerosis (MS);~~
~~wherein said human polypeptide binds said HLA-DR protein, and activates autoreactive T cells from a subject having said autoimmune disease; , and;~~
 wherein said ~~human~~ polypeptide is a non-myelin basic protein polypeptide.

33-34. (Canceled)

35. (Currently Amended) The ~~pharmaceutical preparation~~ composition of claim 33 ~~32,~~
 wherein said polypeptide consists of ~~an~~ the amino acid sequence set forth in ~~selected from~~ SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7.

36-39. (Canceled)

40. (Currently Amended) The ~~pharmaceutical preparation~~ composition of claim 33 ~~35,~~
 wherein said polypeptide consists of ~~an~~ the amino acid sequence set forth in ~~selected from~~ SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 7.

41-42. **{Canceled}**

43. **(New)** The composition of claim 32, wherein the polypeptide is 15 amino acids in length.

44. **(New)** A composition comprising

(i) a pharmaceutically acceptable carrier, and

(ii) an isolated polypeptide consisting of an amino acid sequence, wherein said amino acid sequence

(a) defines a sequence motif containing core MHC binding residues comprising MS motif #1 (SEQ ID NO: 18), and

(b) is based upon the structure of the binding pocket of an DRB1*1501 protein that is associated with multiple sclerosis,

wherein said polypeptide is a non-myelin basic protein polypeptide.

45. **(New)** A composition comprising

(i) a pharmaceutically acceptable carrier, and

(ii) an isolated polypeptide consisting of an amino acid sequence, wherein said amino acid sequence

(a) defines a sequence motif containing core MHC binding residues comprising MS motif #2 (SEQ ID NO: 19), and

(b) is based upon the structure of the binding pocket of an DRB1*1501 protein that is associated with multiple sclerosis,

wherein said polypeptide is a non-myelin basic protein polypeptide.

46. **(New)** A composition comprising

(i) a pharmaceutically acceptable carrier, and

(ii) an isolated polypeptide consisting of an amino acid sequence, wherein said amino acid sequence

(a) defines a sequence motif containing core MHC binding residues comprising MS motif #2 (SEQ ID NO: 20), and

10046908_1

(b) is based upon the structure of the binding pocket of an DRB1*1501 protein that is associated with multiple sclerosis, wherein said polypeptide is a non-myelin basic protein polypeptide.